IN RE THALOMID REVLIMID LITIGATION

United States District Court for the District of New Jersey

IF YOU PURCHASED THE PRESCRIPTION DRUGS THALOMID OR REVLIMID, YOUR RIGHTS MAY BE AFFECTED, AND YOU COULD GET A PAYMENT FROM A CLASS ACTION SETTLEMENT.

On December 23, 2019, Celgene exercised its right to rescind the settlement agreement. As a result, we are no longer processing claims in this matter. More information, including plaintiffs’ letter to the Court regarding the rescission, can be found on the Court Documents page. 

A settlement was reached with Celgene Corporation ("Celgene") in a class action lawsuit about whether it acted to keep generic versions of Thalomid and Revlimid off the market.  You were a Settlement Class Member if you were:

Celgene had agreed to settle the lawsuit for $55 million.

You were included in this settlement if you are a Third Party Payor or consumer that paid for all or some of the purchase price of Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before August 1, 2019. 

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT:

SUBMIT A CLAIM FORM:

Settlement Rescinded.  No longer accepting claims. 
EXCLUSION DEADLINE: December 2, 2019

If you decide to exclude yourself or your entity, you will keep the right to sue Celgene in a separate lawsuit about the claims this settlement resolves, but you give up the right to get a payment from this settlement. 

This is the only option that allows you to sue, continue to sue, or be part of another lawsuit against Celgene related to the legal claims in this case. 

OBJECTION DEADLINE: December 2, 2019 If you want to remain a Settlement Class Member, you may object to it by writing to the Court about why you don't like the settlement.

Your rights are affected whether you act or do not act.  Therefore, you should read the Notice carefully.